Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HS-20093 + bevacizumab + 5-fluorouracil
- Development stage
- Phase 1
- Lead developer
- Hansoh Pharmaceutical Group
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
HS-20093 + bevacizumab + 5-fluorouracil is an experimental combination regimen under evaluation for advanced or metastatic solid tumors. - **HS-20093** is a fully humanized IgG1 antibody-drug conjugate (ADC) targeting B7-H3, a protein highly expressed in various solid tumors, delivering a cytotoxic payload to kill cancer cells. - **Bevacizumab** is a humanized monoclonal antibody that targets and inhibits vascular endothelial growth factor A (VEGF-A), thus blocking tumor angiogenesis. - **5-fluorouracil** is a pyrimidine analog antimetabolite that inhibits thymidylate synthase, interfering with DNA synthesis and inducing cytotoxic effects on rapidly dividing tumor cells. This combination aims to synergistically enhance antitumor effects through direct cytotoxicity, inhibition of tumor angiogenesis, and blockade of key growth pathways. This regimen is currently being studied in patients with advanced solid tumors, including those refractory to prior treatments, in early-phase clinical trials[8][4][6].
- Other names
- 5-fluorouracil
02
Targets
Beyond the preview
Go deeper on HS-20093 + bevacizumab + 5-fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HS-20093 + bevacizumab + 5-fluorouracil.